Physician profile
Clement C Hsiao
NPI 1477512085
$1,942.07
in general payments reported to CMS, 2019-2025
26 companies · $37.58 in 2025
The $37.58 reported for 2025 was less than what a typical Obstetrics & Gynecology provider received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $218 · 2020: $249 · 2021: $317 · 2022: $428 · 2023: $600 · 2024: $91.45 · 2025: $37.58.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $379 · Consulting Fee: $350.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $379.04 |
| Consulting Fee | $350.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $481.04 | 2019-2023 | |
| Meditrina | $350.00 | 2023 | |
| Aspira Women'S Health INC | $160.62 | 2021-2022 | |
| Mayne Pharma Commercial LLC | $132.60 | 2022-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $117.71 | 2019-2023 | |
| Myovant Sciences INC. | $103.08 | 2022 | |
| Astellas Pharma US INC | $84.10 | 2020-2023 | Veozah |
| Novo Nordisk INC | $79.45 | 2020-2023 | Wegovy, Saxenda |
| Sumitomo Pharma America, INC. | $71.17 | 2023-2025 | Myfembree |
| Avion Pharmaceuticals | $62.15 | 2021 | |
| Therapeuticsmd, INC. | $43.97 | 2020-2021 | |
| Alydia Health | $28.65 | 2021 | |
| Lupin INC. | $28.39 | 2019-2020 | |
| Coopersurgical, INC. | $22.26 | 2022 | |
| Mycovia Pharmaceuticals, INC. | $20.24 | 2023 | Vivjoa |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $19.50 | 2024 | Zepbound |
| Pfizer INC. | $18.10 | 2023 | |
| Roche Diagnostics Corporation | $17.74 | 2019 | |
| Baxter Healthcare | $16.50 | 2021 | |
| Exact Sciences Corporation | $16.38 | 2024 | Cologuard Collection Kit |
| Millicent US INC | $15.49 | 2020 | |
| Ascend Therapeutics US, LLC | $15.39 | 2023 | |
| Virtus Pharmaceuticals LLC | $13.32 | 2021 | |
| Axonics, INC. | $12.13 | 2020 | |
| Organon LLC | $12.09 | 2022 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$5.00 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Clement Hsiao listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.